Toxic maculopathy due to antimalarial drugs

Toxic maculopathy due to antimalarial drugs, also known as antimalarial retinopathy or chloroquine/hydroxychloroquine retinopathy, is an acquired condition in which long-term use of antimalarial medications—most commonly chloroquine and hydroxychloroquine—causes progressive damage to the macula, the central part of the retina responsible for sharp, detailed vision. These medications are widely prescribed not only for malaria prophylaxis but also for autoimmune and inflammatory conditions such as systemic lupus erythematosus and rheumatoid arthritis. The toxic effect is dose-dependent and cumulative, meaning that risk increases with higher daily doses, longer duration of use, and higher cumulative lifetime exposure. The condition primarily affects the eye, specifically the retinal pigment epithelium and photoreceptor cells of the macula. In early stages, patients may be asymptomatic, but structural changes can be detected on specialized imaging such as optical coherence tomography (OCT) and fundus autofluorescence. As the disease progresses, a characteristic 'bull's eye maculopathy' pattern may develop on fundoscopy, with a ring of depigmented retinal pigment epithelium surrounding a darker central area. Patients may experience difficulty reading, blurred central vision, paracentral scotomas (blind spots near the center of vision), decreased color vision, and difficulty adapting to dim lighting. In advanced cases, significant and irreversible vision loss can occur. There is no established treatment to reverse retinal damage once it has occurred, making early detection through regular screening essential. Current guidelines recommend baseline ophthalmologic examination before or within the first year of starting therapy, followed by annual screening after five years of use (or sooner in patients with additional risk factors such as renal impairment or concurrent tamoxifen use). The primary management strategy is discontinuation of the offending drug upon detection of early retinal toxicity, which may halt or slow progression. Patients and prescribing physicians must carefully weigh the benefits of antimalarial therapy against the risk of irreversible visual damage.

Common questions about Toxic maculopathy due to antimalarial drugs